Scarica l'app Stockscreener
4.76
4.62%
0.21
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040 - GlobeNewswire Inc.
COYA: Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027 - TradingView
Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish - Streetwise Reports
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com - Investing.com UK
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn
Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News
Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
COYA Q1 2026 Earnings: 24.1% EPS Beat Narrows Loss, Shares Rise 1.72%Margin Expansion Trends - vinanet.vn
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coya Therapeutics (COYA) Rallies 3.71% as Shares Press Toward Key $5 LevelMarket Profile - dars.gov.et
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.7% Stock UptickMargin Improvement Report - vinanet.vn
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 24.1% EPS Surprise, Shares Rise 2.7%Margin Expansion Trends - vinanet.vn
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 5.4%Net Profit Margin - vinanet.vn
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleNegative Gamma - vinanet.vn
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineQuarterly Profit Report - vinanet.vn
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
COYA Q1 2026 Earnings: Narrower Loss Beats Street Estimate Amid Pre-Revenue ProgressOne-Time Loss Impact - vinanet.vn
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates as Biotech Priorities Cash RunwaySlow Growth Warning - vinanet.vn
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to sales forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support LevelsBear Pennant - dars.gov.et
Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
Coya Therapeutics (COYA) Holds Steady at $5.26 as Trading Range NarrowsIV Crush Alert - dars.gov.et
Coya Therapeutics(COYA) Stock Options Chain | Quotes & News - Moomoo
Coya Therapeutics (COYA) Slips 1.87% as Stock Tests Key Support Near $5.00Triple Top - dars.gov.et
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI) - The Globe and Mail
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):